Physician profile
Lawrence E Samuels
NPI 1811983869
$19,317.36
in general payments reported to CMS, 2019-2025
51 companies · $4,069 in 2025
The $4,069 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,458 · 2021: $2,314 · 2022: $2,318 · 2023: $3,167 · 2024: $4,293 · 2025: $4,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,269.11 |
| Education | $259.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,542.64 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $1,865.72 | 2019-2025 | |
| Janssen Biotech, INC. | $1,567.92 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,321.99 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $1,109.19 | 2020-2025 | Adbry, Anzupgo |
| Amgen INC. | $961.05 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $889.63 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $721.78 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $708.88 | 2020-2025 | Aklief, Nemluvio, Oracea |
| Sun Pharmaceutical Industries INC. | $643.66 | 2019-2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $626.84 | 2019-2025 | |
| Allergan, INC. | $578.51 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $572.30 | 2023-2025 | Zoryve |
| Incyte Corporation | $505.89 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $430.72 | 2022-2024 | Vtama |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Samuels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.